Experimental pill combo takes on tough leukemia

NCT ID NCT05287568

Recruiting now Disease control Sponsor: University of Colorado, Denver Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial is testing two oral drugs, CC-486 and venetoclax, together in people with acute myeloid leukemia (AML) that has relapsed or not responded to prior treatment. The main goal is to find the safest dose of CC-486 when combined with venetoclax, and to monitor side effects. Up to 35 participants will take part in this open-label study at a single center.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: CC-486 (oral azacitidine) and venetoclax
What this could lead to: If this works, it could offer a new treatment option for people with acute myeloid leukemia that has come back or not responded to other therapies.
What could go wrong: This is a very early Phase 1 trial with only 35 participants, so it is mainly checking safety and dosing. It may not lead to an effective treatment, and side effects are still being studied.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AML are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

AML

Contacts and locations

Locations

CU Anschutz Medical Campus
RECRUITING

Aurora, Colorado, 80045, United States
University of Colorado Hospital
RECRUITING

Aurora, Colorado, 80045, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.